Merck Raises 2026 Revenue to $66.3B–$67.3B but EPS Drops ~47% to $2.66–$2.76 After Terns Deal Charges — Leverage Scenarios for MRK CFDs

Event Summary

Merck & Co. (NYSE: MRK) has revised its full-year 2026 guidance following completion of the Terns Pharmaceuticals acquisition, as reported by Benzinga and Yahoo Finance. Revenue guidance was raised to $66.3B–$67.3B (from $65.8B–$67.0B prior), while adjusted EPS was cut sharply to $2.66–$2.76 from the prior range of $5.04–$5.16 — a ~47% midpoint decline. The EPS compression is mechanically driven by $2.43 per share in Terns-related charges: a $2.31/share one-time charge plus ~$0.12/share in ongoing financing and development costs for MK-4208 (formerly TERN-701). These charges compound earlier charges tied to the Cidara Therapeutics acquisition ($3.62/share). Merck's core business — anchored by Keytruda's oncology franchise — remains the underpinning of the raised revenue outlook.

The revised EPS is at or slightly below analyst consensus of ~$2.76, while revenue is marginally above consensus of ~$66.8B. This is a nuanced print: headline EPS shock, but underlying operating trends intact. This fits squarely within the pharma & fintech acquisition repricing theme that has driven MRK volatility across recent quarters.

Leverage Impact Analysis

With MRK trading at $128.51 (24h range: $126.27–$129.98, up +0.86%), leveraged CFD traders face a bifurcated setup.

Long scenario: A trader holding a 50x long MRK CFD entered at $126.50 sees a current mark-to-market gain of ~$2.01/share × 50 = ~$100.50 per share of notional exposure — healthy on paper but exposed to reversal if institutional investors interpret the ~47% EPS cut as signal of further deal-related dilution ahead.

Short squeeze risk: Traders who shorted MRK on the EPS headline may face pressure if the market correctly re-reads the charge as non-recurring. A 100x short CFD opened at $128.51 faces a $1.47/share loss (to 24h high of $129.98), equivalent to $147 per share of notional — at 100x, that represents ~1.15% adverse move triggering meaningful margin erosion.

Key leverage consideration: Because the EPS drop is accounting-driven (deal charges) rather than fundamental deterioration, implied volatility may remain elevated as the market reprices between "headline EPS" bears and "underlying EPS" bulls. Position sizing should account for sharp intraday swings. Check live margin requirements on CoinUnited.io before sizing MRK CFD positions.

Cross-Market Impact

This event is pharma-specific with limited macro spillover, but sector-level read-throughs matter. Pfizer and Bristol-Myers Squibb may see incremental sentiment pressure if the market interprets Merck's EPS dilution from bolt-on M&A as a sector-wide pattern. Conversely, Eli Lilly — which has avoided large M&A charges — could attract relative-value inflows. For a deeper look at how oncology deals ripple across pharma names, see the Pharma M&A Playbook.

At the index level, MRK is a meaningful S&P 500 healthcare constituent. A ~47% headline EPS revision could modestly weigh on sector-level earnings aggregates, though the effect on the broader NASDAQ 100 is negligible given MRK's non-tech weighting. Small/mid-cap oncology biotech names may benefit from the deal's read-through: Merck's willingness to pay deal premiums for pipeline assets supports takeover valuations across the sector, consistent with the broader energy, pharma & tech acquisition wave.

FX and commodities are not directly impacted. Merck previously noted ~1 ppt FX tailwind on revenue and ~$0.10/share on EPS, confirming USD sensitivity but not creating actionable FX flows from this guidance revision alone.

Trading Considerations

MRK is trading in a $126.27–$129.98 intraday range. The key level to watch is whether price sustains above $128.51 on close — a hold signals the market is looking through accounting charges toward the raised revenue outlook and pipeline optionality. A break below $126.27 (intraday low) would suggest headline EPS sellers dominating near-term. For how to trade earnings beats and guidance revisions in large-cap pharma, leverage-aware entry timing and stop discipline remain critical given elevated implied vol around deal-related charge quarters.

Trade Merck & Co., Inc. on CoinUnited.io

Trade MRK with up to 1000xx leverage → | Create Free Account